Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Resistance Exercise, Muscle Weakness, Fu...
Phase NA
Enrollment 62
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

With improved a five-day intensive, low-resistance elastic band exercise program to evaluate its effectiveness in improving total muscle mass, upper and lower extremity muscle strength, self-perceived fear of falling, and depression among hospitalized elderly individuals. This study is a random control trial. Data collection includes elderly patient's total muscle mass, upper and lower extremity muscle strength, self-perceived fear of falling, and depression among hospitalized. The total muscle mass and upper and lower extremity muscle strength will be calculated in kilograms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Device: Elastic Band — Using the newly patented product, the Muscle Exercise and Falling Prevention Elastic Strap (Patent Certificate No. M585601), the procedure involves securing the elastic strap to a high-back chair to administer elastic band intervention exercises for patients.Guided by continuous contextual action demonstration videos, participants will engage in the elastic band resistance intervention twice a day, each session lasting 20 minutes, over a span of five days. These videos are designed to provide a continuous contextual demonstration, incorporating them within the video itself.

Primary Outcomes

  • total muscle mass and upper and lower extremity muscle strength (20 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-05
Completion: 2025-12-31
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 62 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University
Contact Information
Study Contact:
PIAO-YI CHIOU, doctoral
+886-2-23123456
piaoyi@ntu.edu.tw
PIAO-YI CHIOU, doctoral
+886-2-23123456
piaoyi@ntu.edu.tw
School of Nursing of National Taiwan University
Interventions
  • Device: Elastic Band — Using the newly patented product, the Muscle Exercise and Falling Prevention Elastic Strap (Patent Certificate No. M585601), the procedure involves securing the elastic strap to a high-back chair to administer elastic band intervention exercises for patients.Guided by continuous contextual action demonstration videos, participants will engage in the elastic band resistance intervention twice a day, each session lasting 20 minutes, over a span of five days. These videos are designed to provide a continuous contextual demonstration, incorporating them within the video itself.
Study Locations (1 sites)
School of Nursing of National Taiwan University, Taipei, Taiwan 100 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Age of 65 years or older. 2. Anticipated hospital stay exceeding 7 days. 3. Able to follow instructions. 4. Four-limb muscle strength of at least three points, and grip strength measurements with a minimum of 26 kilograms for males and 18 kilograms for females. Exclusion Criteria: 1. This includes individuals with cardiovascular diseases such as acute myocardial infarction, unstable angina, poorly controlled arrhythmias, complete atrioventricular block, acute heart failure, acute myocarditis, acute pericarditis, and other cardiac conditions. 2. Poorly controlled hypertension, with systolic blood pressure less than 90 mmHg or greater than 200 mmHg under medication. 3. Individuals hospitalized due to acute neurological injuries or conditions, such as epilepsy, stroke, or Parkinson's disease. 4. Diagnosed with cognitive impairment or Alzheimer's disease. 5. Those who require long-term ventilator support and are unable to participate in the program. 6. Individuals with impaired consciousness who cannot cooperate. 7. A Glasgow Coma Scale score of less than 12, or inability to correctly answer questions about person, time, place, or follow instructions.
Conditions Hypertension, Treatment Adherence and Co...
Phase NA
Enrollment 206
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Inadequate medication adherence (MA) in chronic conditions, including cardiovascular prevention, represents an important risk factor. The use of new IT technologies in this setting is supposed to be useful to improve patients' adherence, but currently available solutions have significant limitations, including lack of personalization and reliance on expensive ad hoc systems. This interdisciplinary project aims to verify the hypothesis that in patients on chronic antihypertensive treatment MA can be improved through the implementation of a novel digital health solution for MA monitoring and support, based on inexpensive and user-friendly, commercially available technology (voice assistant), connected with web interface for the physician. The intervention will be personalized based on the creation of Personas, intended as multidisciplinary-based representations of different user types. This approach will be tested in a randomized clinical trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: adherence support system based on a vocal assistant — Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken. Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre.

Primary Outcomes

  • Adherence (plasma essay - 3m) (after 3 months of randomized intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-01
Completion: 2026-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 206 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituto Auxologico Italiano
Collaborators: Istituti Clinici Scientifici Maugeri SpA, Politecnico di Milano
Principal Investigators:
  • Grzegorz Bilo, MD, PhD (PRINCIPAL_INVESTIGATOR) - Istituto Auxologico Italiano
Contact Information
Study Contact:
Grzegorz Bilo, MD, PhD
+390261911
g.bilo@auxologico.it
Lucia Zanotti, Bsc, PhD
+390261911
l.zanotti@auxologico.it
Lucia Zanotti
+39 02 619112714
l.zanotti@auxologico.it
San Luca Hospital, Istituto Auxologico Italiano IRCCS
Interventions
  • Other: adherence support system based on a vocal assistant — Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken. Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre.
Study Locations (1 sites)
San Luca Hospital, Istituto Auxologico Italiano IRCCS, Milan, 20149 Italy
Eligibility Criteria
Inclusion Criteria: * Adult (\>18 years old) patients * History of essential hypertension * Treatment with at least one antihypertensive drug for which dedicated plasma essay is available * wireless internet connection available at patients' home * stable clinical conditions * written informed consent Exclusion Criteria: * insufficient technological literacy to manage vocal assistant * dementia or significant psychiatric disorders * conditions significantly limiting vocal communication (deafness, significant speech disorders, poor knowledge of Italian language) * pregnancy or breastfeeding * active cancer (except basal cell skin carcinoma) * upper limb amputation
Conditions Depression
Phase NA
Enrollment 146
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Intermittent theta burst stimulation (iTBS), a variant of repetitive transcranial magnetic stimulation (rTMS), is a well documented method for treatment of depression. The aim of the study is to assess the effect of an accelerated iTBS protocol compared to a routine iTBS protocol. In the accelerated protocol patients will receive 1200 pulses per session (2 sessions per day, 15 treatment days) and in the routine protocol patients will receive 600 pulses per session (1 session per day, 30 treatment days). Participants (n = 146) will be recruited among patients referred to iTBS and randomized to treatment. Participants will be assessed by a psychiatrist, or a resident psychiatrist, prior to treatment to assure that they fulfill all inclusion criteria and non of the exclusion criteria. A psychiatrist, or a resident psychiatrist, will assess depressive symptoms 3 and 6 weeks after first day of treatment. Patients will complete self-rating questionnaires during screening, weekly for 6 weeks starting from the first day of treatment, and 6 months after end of treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: iTBS (intermittent theta-burst stimulation) — The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.

Primary Outcomes

  • Difference in MADRS-S from baseline to three weeks after first iTBS treatment (3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-15
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 146 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Collaborators: Göteborg University, Uppsala University, The Swedish Society of Medicine
Principal Investigators:
  • Melker Hagsäter, MD, MSc, PhD (PRINCIPAL_INVESTIGATOR) - Västra Götaland Regional Council
Contact Information
Study Contact:
Melker Hagsäter, MD, MSc, PhD
+46 3039 8000
melker.hagsater@vgregion.se
Melker Hagsäter
+46 10441 00 00
melker.hagsater@vgregion.se
Kungälv Hospital
Interventions
  • Device: iTBS (intermittent theta-burst stimulation) — The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.
Study Locations (2 sites)
Kungälv Hospital, Kungälv, Sweden
Hospital of Skövde, Skövde, Sweden
Eligibility Criteria
Inclusion Criteria: * diagnosis of depression verified through a Mini International Neuropsychiatric Interview (M.I.N.I.) * MADRS-S \>= 20 * unchanged medication last month * unchanged psychological treatment last month * admitted to psychiatric ward last month * no ECT or TMS last six months * provision of signed informed consent form * indication for TMS is depression Exclusion Criteria: * addiction (illicit drugs or alcohol) * pregnancy * epilepsy * conductive ferromagnetic or other metals implanted in the head or within 30 cm of the treatment coil * implanted device that is activated or controlled in any way by physiological signals * implanted mediation pumps * intracardiac lines, even when removed * regular use of benzodiazepines * any condition that seriously increases the risk of non-compliance or loss of follow-up
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Psilocybin — COMP360 (Brand name of psilocybin to be used)

Primary Outcomes

  • Change in Massachusetts General Hospital Rumination Questionnaire (MGH-RQ) (Baseline, and 3 weeks, 6 weeks, 9 weeks, and 12 weeks after psilocybin administration.)
  • Change in Resting-State Functional Connectivity (Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration.)
  • Change in Self-Attribution Task performance (Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration.)
  • Change in Task-Based Activity during Self-Attribution Task (Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-09-10
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sharmin Ghaznavi
Collaborators: COMPASS Pathways
Principal Investigators:
  • Sharmin Ghaznavi, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Artana Arora, B.S.
6177262290
cnpcogneuro@mgh.harvard.edu
Artana Arora
cnpcogneuro@mgh.harvard.edu
Athinoula A. Martinos Center for Biomedical Imaging
Interventions
  • Drug: Psilocybin — COMP360 (Brand name of psilocybin to be used)
Study Locations (1 sites)
Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129 United States
Eligibility Criteria
Inclusion Criteria: 1. Must be able to sign the informed consent form (ICF). Participants will demonstrate capacity to provide informed consent by demonstrated understanding of the protocol and what their involvement in the study requires from them. 2. Be 18-55 years of age at screening. 3. At least moderate Major Depressive Disorder (MDD; single or recurrent episode as informed by Diagnostic and Statistical Manual Version 5 (DSM-V); if single episode, duration of ≥ 3 months and ≤ 3 years) based on clinical assessment and a structured clinical interview, the Mini International Neuropsychiatric Interview Version 7.02 (MINI).43 4. Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS)44 score ≥ 18 at Screening and at Baseline. 5. Failure to respond to an adequate dose and duration of 1, 2, 3, or 4 pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment History Response Questionnaire (MGH-ATRQ)45 and using the supplementary advice on additional antidepressants not included in MGH-ATRQ. Augmentation with an add-on treatment counts as a second treatment, provided it is approved for the adjunctive treatment of MDD. 6. McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) \< 7 at Screening. 7. Participants will also have to successfully undergo a taper off of all psychotropic medications under the supervision of a study psychiatrist and in coordination with their treatment team, which will be completed at least 2 weeks prior to Baseline Scan. Please see below regarding details about discontinuation of antidepressants. 8. A score \> 40 on the Wechsler Test of Adult Reading.46 9. Be right-handed as determined by the Edinburgh Handedness Inventory.48 10. Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits. 11. Have ongoing established mental health care. Exclusion Criteria: Patients meeting any of the following criteria are to be excluded from the study: 1. Current, past history, or family history, of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, or any serious psychiatric comorbidity as assessed by medical history and a structured clinical interview (version 7.0.2 MINI). 2. Positive Magnetic Resonance screen (e.g., metal implant, claustrophobia, etc). 3. Prior electroconvulsive therapy and/or ketamine for current episode. 4. Current cognitive behavioral therapy (CBT) that will not remain stable for the duration of the study. CBT cannot be initiated within 21 days of Baseline. 5. Current (within the last year) alcohol or substance abuse as informed by DSM-5 at Screening. 6. Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS)49 within the past year, at Screening or at Baseline, or; (2) suicidal behaviors within the past year, or; (3) clinical assessment of significant suicidal risk during clinical interview. 7. Significant homicide risk as defined by clinical interview. 8. Depression secondary to other severe medical conditions. 9. Currently taking benzodiazepines daily. 10. Other personal circumstances and behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin, as well as exposure to psilocybin or other psychedelics within one year of screening. 11. Women who are pregnant, nursing, or planning a pregnancy. Participants who are sexually active must agree to use a highly effective contraceptive method throughout their participation in the study. Women of childbearing potential must have a negative urine pregnancy test at Screening and Day Before Psilocybin. 12. Cardiovascular conditions: recent stroke (\< 1 year from signing of consent), recent myocardial infarction (\< 1 year from signing of ICF), hypertension (blood pressure \> 140/90 mmHg) or corrected QT interval \> 450 msec) or clinically significant arrhythmia within 1 year of signing the ICF, current anticoagulant therapy, aneurysmal disease. 13. Uncontrolled insulin dependent diabetes. 14. Seizure disorder. 15. Positive urine drug screen for illicit drugs or drugs of abuse (to include but not limited to opiates, phenylcyclohexyl piperidine(PCP), cocaine, amphetamines, methamphetamines, benzodiazepines, barbiturates, and cannabis) at Screening and Day Before Psilocybin. Any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion. 16. Lifetime history of surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system (CNS) disorder (e.g., Alzheimer's or Parkinson's Disease), epilepsy, mental retardation, or any other disease/procedure/accident/intervention which, according to the screening clinician, is deemed associated with significant injury to or malfunction of the CNS, or history of significant head trauma within the past 2 years. 17. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation. 18. Current enrollment in any investigational drug or device study or participation in such within 6 months of Screening. 19. Current enrollment in an interventional study for depression or participation in such within 6 months of Screening Visit. 20. Non-native speakers of English.
Conditions Breast Cancer, Familial Male, Radiothera...
Phase NA
Enrollment 148
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4/6 inhibitors, PARP inhibitors, capecitabine and PD1 inhibitors have greatly improved the prognosis of breast cancer and has become the standard treatment for specific populations. A considerable number of patients require both radiotherapy and maintenance systemic therapy. However, it is not clear whether systemic therapy should be synchronized or suspended in radiotherapy,despite that previous basic research shows that some molecular drug therapy and radiotherapy has a clear synergy mechanism. There is an agent need for a definite evidence to evaluate the safety of synchronous treatment, to support clinical diagnosis and treatment and the next step of comprehensive treatment. The implementation of the new radiotherapy technology represented by IMRT takes into account the prescription dose homogenization and the minimization of normal tissue dosage, which provides a certain basis for the combination therapy. Based on the above conditions, this study intends to enroll patients between 18 and 70 years old with chest wall / breast ± lymphatic drainage area and requiring capecitabine, CDK 4/ 6 inhibitor, HER2 targeted therapy or immunotherapy. Radiation and novel systemic therapies would be delivered concurrently. The study aimed at evaluating the safety of combined treatments.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients) — Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.

Primary Outcomes

  • Grade 3 adverse events (Every week during the radiation , week 4 and week 12 after radiation, and at any time when severe symptoms were recorded within 3 months after radiation.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-12
Completion: 2027-01-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 148 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigators:
  • Yirui Zhai, MD (PRINCIPAL_INVESTIGATOR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Bo Lan, MD (PRINCIPAL_INVESTIGATOR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Shulian Wang, MD (STUDY_CHAIR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Yirui Zhai, MD
+86-10-87788058
januarywind@163.com
Bo Lan, MD
Yirui Zhai, MD
+86-10-87788058
januarywind@163.com
Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Interventions
  • Radiation: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients) — Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.
Study Locations (1 sites)
Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: ECOG 0-2. Aged 18-70 years old. Pathologically diagnosed as breast cancer. Need to receive radiotherapy according to guidelines. Radiotherapy target volume included chest wall/breast with or without lymph node regions. Need to receive one of the following therapies according to guidelines, capetabine, CDK4/6 inhibitor, PARP inhibitor , ICIs , HER2 inhibitors. Exclusion Criteria: Male breast cancer. Allergy to the upper medicines before. Will receive trastuzumab alone during and/or after radiotherapy. With severe other disease.
Conditions Adolescent Behavior, Adolescent - Emotio...
Phase NA
Enrollment 216
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Purpose: The purpose of this research is to pilot test a novel, alternative, potentially sustainable system of teacher-delivered, task-shifted adolescent mental health care. Participants: Principals of 60 rural, low-cost private secondary schools of the Darjeeling Himalayas will be invited to participate as a school and an individual. Teachers will be approached individually. Two students per teacher who meet inclusion criteria will be randomly chosen for enrollment. Procedures: This is a RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) guided, mixed methods CRCT, clustered at schools, of Tealeaf-A's Reach, Adoption \& Implementation (Primary Outcomes, implementation-based), as well as evaluating for preliminary indicators of Effectiveness \& Maintenance (Secondary Outcomes, clinically-based).

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Crossover Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Tealeaf-Mansik Swasta (Tealeaf) as adapted for Adolescents — The investigators will test Tealeaf (Teachers Leading the Frontlines - Mansik Swastha \[Mental Health in Nepali\]) as adapted for adolescents. Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Created in Darjeeling, Tealeaf centers on training and supervising teachers to deliver "education as mental health therapy" (Ed-MH) to children (age 5-12). Ed-MH is the investigators' novel, task-shifting, therapy modality that minimizes the time teachers need to deliver care by fitting it into their work. In Ed-MH, teachers use evidence-based therapeutic techniques adapted for use in their existing interactions with students in need (e.g., while teaching) and streamlined for care for any diagnosis ("transdiagnostic"). Tealeaf-A's adaptation (inclusive of Ed-MH) is supported by a Doris Duke Charitable Foundation (DDCF), Fund to Retain Clinical Scientists (FRCS), Caregivers at Carolina COVID award.
  • Behavioral: Enhanced Usual Care (EUC) — Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.

Primary Outcomes

  • Mean Number of Dropouts (Reach) (Month 9 of Academic Years 1 and 2)
  • Applied Mental Health Research Dissemination and Implementation Adoption Scale scores (Adoption) (Month 0, Month 9 of Academic Years 1 and 2)
  • Applied Mental Health Research Dissemination and Implementation Adoption Scale scores (Implementation) (Month 9 of Academic Years 1 and 2)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-29
Completion: 2027-02-01
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: University of North Bengal, India, Darjeeling Ladenla Road Prerna, Broadleaf Health and Education Alliance, University of Colorado, Denver, Doris Duke Charitable Foundation
Principal Investigators:
  • Christina Cruz, MD; EdM (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Christina Cruz, MD; EdM
347-721-1458
christina_cruz@med.unc.edu
Michael Matergia, MD
857-488-7209
michael.matergia@broadleafhea.org
Priscilla Giri
+91 354 2255894
priscillagiri22@gmail.com
Darjeeling Ladenla Road Prerna
Interventions
  • Behavioral: Tealeaf-Mansik Swasta (Tealeaf) as adapted for Adolescents — The investigators will test Tealeaf (Teachers Leading the Frontlines - Mansik Swastha \[Mental Health in Nepali\]) as adapted for adolescents. Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Created in Darjeeling, Tealeaf centers on training and supervising teachers to deliver "education as mental health therapy" (Ed-MH) to children (age 5-12). Ed-MH is the investigators' novel, task-shifting, therapy modality that minimizes the time teachers need to deliver care by fitting it into their work. In Ed-MH, teachers use evidence-based therapeutic techniques adapted for use in their existing interactions with students in need (e.g., while teaching) and streamlined for care for any diagnosis ("transdiagnostic"). Tealeaf-A's adaptation (inclusive of Ed-MH) is supported by a Doris Duke Charitable Foundation (DDCF), Fund to Retain Clinical Scientists (FRCS), Caregivers at Carolina COVID award.
  • Behavioral: Enhanced Usual Care (EUC) — Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
Study Locations (1 sites)
Darjeeling Ladenla Road Prerna, Darjeeling, West Bengal 734101 India
Eligibility Criteria
Inclusion Criteria: Schools: * LCP (Low-Cost Private) Secondary Schools * Enrolled families earning \<$10 daily * Located in greater Darjeeling * Principal must also be eligible to participate Principals: * \>18 years old * Employed at enrolled school * Not suspected or convicted of child maltreatment Teachers: * \>18 years old * Employed at enrolled school * Not suspected or convicted of child maltreatment Students: * Age 13 - 17 years * Student of enrolled teacher * Borderline or clinical Total Problem or subscale score of YSR (Youth Self-Report) and TRF (Teacher's Report Form) * Each student has a lead teacher (2/teacher), with their other teachers also involved Guardians * \>18 years old * Guardian of enrolled student * Not suspected or convicted of child maltreatment Exclusion Criteria: * Exclusion criteria will be set as each participant not meeting inclusion criteria as set for their group.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 100
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Ciclibiome is a prospective study including BC patients starting treatment with a CDK4/6 inhibitor (in the metastatic and in the adjuvant setting). This study will focus on the interplay between the gut microbiome (its composition and evolution during treatment), circulating immune, metabolic and cytokine biomarkers (before and during treatment), and response outcomes to the CDK4/6 inhibitor. The main aim of the study is to highlight the existence of a microbial, immune and/or metabolic biomarker of response to CDK4/6 inhibition in BC, assessable by a stool or blood sample examination. Ultimately, this will allow to study new potential combination partners for CDK4/6 inhibitors in escalation trials for poor prognosis patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Pre-treatment gut microbiome composition (at study inclusion)
  • Pre-treatment gut metabolic profile (at study inclusion)
  • Pre-treatment circulating immune population profile (at study inclusion)
  • Pre-treatment circulating metabolic profile (at study inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-15
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators: Jules Bordet Institute
Principal Investigators:
  • Cédric Van Marcke, MD, PhD (PRINCIPAL_INVESTIGATOR) - Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact Information
Study Contact:
Cédric Van Marcke, MD, PhD
+3227645106
cedric.vanmarcke@saintluc.uclouvain.be
Elodie Villar
+3227647938
elodie.villar@saintluc.uclouvain.be
Laetitia Collet, MD
+3225413111
laetitia.collet@hubruxelles.be
Institut Jules Bordet
Interventions
N/A
Study Locations (3 sites)
Institut Jules Bordet, Brussels, 1070 Belgium
Cliniques universitaires Saint-Luc, Brussels, 1200 Belgium
CHU UCL Namur, Namur, 5000 Belgium
Eligibility Criteria
\* Cohort of metastatic HR-positive HER2-negative breast cancer : Inclusion Criteria: Patients that respond to each of these criteria can be included : * Diagnosis of previously untreated HR+ HER2- advanced breast cancer (defined as locally advanced and unresectable, or metastatic). HR+ defined as positive estrogen receptors as per local laboratory testing. HER2- defined as negative ISH test or an IHC status of 0 or 1+ as per local laboratory testing. * Planned first-line treatment with an endocrine therapy (aromatase inhibitor or fulvestrant) and a CDK4/6i. * Male or female ≥ 18 years of age at the time the informed consent is signed. * Being able to provide written informed consent. * Patients with a history of early breast cancer are allowed providing systemic therapy (including adjuvant endocrine therapy) was discontinued more than 6 months ago. * Patients are willing and able to comply with the protocol for the duration of the study including sample collection. * Paraffin-embedded tumor tissue available at diagnosis of metastatic disease (inclusion to be discussed if not available). Exclusion Criteria: Patients who respond to any of these criteria are excluded : * Administration of the CDK4/6i already started. * Concurrent or previous non breast-related malignancy in the last 3 years prior to the start of the study treatment (with the exception of a history of adequately treated cervical carcinoma in situ or non-melanoma skin cancer). * Treatment or chronic prevention of an infection through oral or intravenous antibiotic administered less than 1 month ago. History of unique antibiotic administration as prophylaxis for an invasive procedure is allowed. * Active disease requiring treatment with an immunomodulatory agent. Low dose oral corticosteroids (equivalent to 8 mg or less of prednisone) or topical corticosteroids are allowed. * Serological positivity for human immunodeficiency virus (HIV) or hepatitis C (HCV). * Known active hepatitis. * Active inflammatory bowel disease or documented malabsorption. * Alcohol consumption (\>3 glasses/day). * Cohort of early HR-positive HER2-negative breast cancer at high risk of relapse : Inclusion criteria : Patients that respond to each of these criteria can be included : * Early HR+ HER2- node-positive breast cancer considered at high risk of relapse (≥ 4 positive lymph nodes, or 1-3 positive lymph nodes and either or both grade 3 or tumor size \> 5 cm). HR+ defined as positive estrogen receptors as per local laboratory testing. HER2- defined as negative ISH test or an IHC status of 0 or 1+ as per local laboratory testing. * Planned adjuvant treatment with a CDK4/6i, in combination with an endocrine therapy (aromatase inhibitor or tamoxifen, with or without LHRH agonists). * Male or female ≥ 18 years of age at the time the informed consent is signed. * Being able to provide written informed consent. * Patients are willing and able to comply with the protocol for the duration of the study including sample collection. * Paraffin-embedded tumor tissue available at diagnosis of the disease or at surgical resection (inclusion to be discussed if not available). Exclusion criteria : Patients who respond to any of these criteria are excluded : * Administration of the CDK4/6i already started. Ongoing administration of the endocrine therapy before study inclusion is allowed. * Concurrent or previous non breast-related malignancy in the last 3 years prior to the start of the study treatment (with the exception of a history of adequately treated cervical carcinoma in situ or non-melanoma skin cancer). * Treatment or chronic prevention of an infection through oral or intravenous antibiotic administered less than 1 month ago. History of unique antibiotic administration as prophylaxis for an invasive procedure is allowed. * Active disease requiring treatment with an immunomodulatory agent. Low dose oral corticosteroids (equivalent to 8 mg or less of prednisone) or topical corticosteroids are allowed. * Serological positivity for human immunodeficiency virus (HIV) or hepatitis C (HCV). * Known active hepatitis. * Active inflammatory bowel disease or documented malabsorption. * Alcohol consumption (\>3 glasses/day).
Conditions Type 1 Diabetes, Type2diabetes
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-centre, multiple cohort, open study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Clinical Demo 2.0 — During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)

Primary Outcomes

  • Glucose changes will be measured noninvasively and transcutaneously in dynamic states of glycaemia (The data is collected during the study procedure (up to 5 hours))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-23
Completion: 2025-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Liom Health AG
Collaborators: Profil Institut für Stoffwechselforschung GmbH
Principal Investigators:
  • Marc Stoffel, MD (PRINCIPAL_INVESTIGATOR) - Profil for Stoffwechselforschung GmbH, Neuss, Germany
Contact Information
Study Contact:
Banu Eyueboglu Seitz, PhD
0041 41 552 00 59
bes@liom.com
Fabien Rebeaud, PhD
0041 41 552 00 59
fr@liom.com
Marc Stoffel, MD
0049213140180
Profil for Stoffwechselforschung GmbH
Interventions
  • Device: Clinical Demo 2.0 — During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)
Study Locations (1 sites)
Profil for Stoffwechselforschung GmbH, Neuss, Nordrhein-Westfallen 41460 Germany
Eligibility Criteria
Inclusion Criteria: * Male or female trial participant with clinically diagnosed type 1 or type 2 diabetes for at least 1 year. * Age between 18 and 65 years, both inclusive. * Treated with insulin and/or oral antidiabetic drugs (OADs; type 2 only), multiple dosing insulin therapy (MDI), continuous subcutaneous insulin infusion (CSII) or a hybrid closed loop system. Exclusion Criteria: * Known or suspected hypersensitivity to any of the components of the Liom Clinical Demo 2.0. * Trial participant with any injury, infection, atypical skin condition (e.g., hyperkeratosis, hyperpigmentation) of or tattoo on the wrists. * Presence or history of a cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias or clinically significant conduction disorders.
Conditions Type 2 Diabetes Treated With Insulin
Phase NA
Enrollment 51
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for three months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision-support algorithms in the management of insulin treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Intelligent telemonitoring — Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
  • Device: Telemonitoring — Telemonitoring using CGM, insulin pen data, and Fitbit data

Primary Outcomes

  • CGM time in range (At baseline to three months after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-15
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 51 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aalborg University Hospital
Collaborators: Novo Nordisk A/S, DexCom, Inc.
Principal Investigators:
  • Peter Vestergaard, MD, PhD (PRINCIPAL_INVESTIGATOR) - Steno Diabetes Center North Denmark
Contact Information
Study Contact:
Jannie Nørlev, PhD
004523676513
jadano@hst.aau.dk
Stine Hangaard, PhD
svh@hst.aau.dk
Katrine Vogensen
004524794472
k.vogensen@rn.dk
Department of Endocrinology
Interventions
  • Device: Intelligent telemonitoring — Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
  • Device: Telemonitoring — Telemonitoring using CGM, insulin pen data, and Fitbit data
Study Locations (1 sites)
Department of Endocrinology, Aalborg, North Jutland 9000 Denmark
Eligibility Criteria
Inclusion Criteria: * Adults ≥ 18 years. * Diagnosis of T2D for at least 12 months prior to the day of screening. * Patients who are being treated with insulin or about to start insulin treatment (insulin naïve) willing to travel to trial site in North Denmark to attend in-person visits. * Have internet at home, have MitID, and willingness to use a smartphone and the other devices used in the trial * Signed informed consent. * Ability to understand and read Danish. Exclusion Criteria: * Pregnancy or breastfeeding. * Major surgery is planned during the trial period. * Cancer diagnosis within five years prior to inclusion. * Participation in other interventional trials. * Limited literacy affecting the use of trial devices. * Patient who has worn a CGM monitor less than 6 months prior to the trial. * Terms that, in the opinion of the sub-investigator or investigator, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participate. * Patients treated with mixed insulin.
Conditions Postnatal Depression
Phase NA
Enrollment 96
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The peripartum period is the period between the last month of pregnancy and up to a year after childbirth. It can be considered a difficult time for women, as it is a period of transition during which vulnerability to psychiatric disorders and in particular to major depressive disorder (MDD) (Vesga-Lopez, Blanco, Olfson, Grant \& Hasin, 2008). Depression with peripartum onset (PPD) is characterised by the fact that the onset of symptoms may occur during pregnancy or within four weeks of delivery, but may also persist for up to 12 months after delivery (American Psychiatric Association, 2013). PPD affects 10 to 20% of women who have given birth (Tebeka et al. 2021). In addition, the psychological distress experienced by the mother during the peripartum period can disrupt interactions with her newborn (Lefkovics et al. 2014). Depression during this period can therefore have long-term consequences, not only for the women who suffer it, but also for their children (Gavin et al. 2005). The investigators now know that women with PPD have deficits in metacognition. Metacognition is the body of knowledge, processes and practices that enable individuals to control and evaluate their own cognitive activities, thereby enabling them to regulate them (Flavell, 1976). Patients with PPD therefore have difficulty identifying, controlling and evaluating their own cognitive activities. These deficits may also represent a risk factor for the development of PPD if they are present at an early stage (Diop et al. 2022). In patients with PPD, metacognitive therapies appear to be effective in reducing symptoms. In 2013, Bevan, Wittkowski and Wells conducted a pilot study to test the effects associated with metacognitive therapy in depression. This was the first published study to evaluate the effects of metacognitive therapy on patients with depression in the peripartum period. It shows promising results which it would be interesting to replicate, as this is a pilot study. A metacognitive training program for depression (D-MCT) was developed by Jelinek, Hauschildt, Moritz and Dubreucq in 2016, it is a brief group intervention that is easy to manage to participants. To date, no study has yet tested this specific program in patients with PPD, but it has been able to show its effectiveness in reducing the metacognitive deficits. In the light of the scientific literature, the aims of this study are, firstly, to demonstrate the efficacy of D-MCT therapy in subjects with post-partum depression. Secondly, to examine the effects of this therapy on mother-child interactions. The investigators make the following assumptions: * Women in the experimental group showed a greater reduction in depressive symptoms and an improvement in metacognitive functioning than those in the control group. * Women in the experimental group showed a reduction in depressive symptoms after therapy (v2) and maintenance of this improvement (v3). * Improvement in the quality of mother-child bonding…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Metacognitive training — Metacognitive training therapy
  • Behavioral: control — management technique as usual

Primary Outcomes

  • Edinburgh Postnatal Depression Scale score (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-10
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CHU de Reims
Contact Information
Study Contact:
Anne Catherine ROLLAND
03 26 78 72 18
acrolland@cu-reims.fr
Damien JOLLY
326788472
djolly@chu-reims.fr
Chu Reims
Interventions
  • Behavioral: Metacognitive training — Metacognitive training therapy
  • Behavioral: control — management technique as usual
Study Locations (1 sites)
Chu Reims, Reims, 51092 France
Eligibility Criteria
Inclusion Criteria: * Women over 18 years * Meets the diagnostic criteria for depressive disorder with peripartum onset (PPD) (APA, 2013) and has already given birth * EPDS score over 10 * Have given their consent to take part in the study * Be affiliated to a social security system * Have an adequate knowledge of written, understood and spoken French (French mother tongue or primary education in the French education system) All women with PPD, whether breastfeeding or not, can be included in the study. Baby care can be organised if mothers are unable to have their babies looked after. This service is provided by nurses from the UPPE in the unit's reception room, which has all the equipment needed to care for infants. Mothers meet the nurses before the group and tell them what they expect, and the nurses give them feedback when they come to collect their baby. Exclusion Criteria: * \- Be the subject of a protection measure * Being a minor * Meets the diagnostic criteria for schizophrenia spectrum disorders (brief psychotic disorder; schizophrenic disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder with peripartum onset) * Meet the criteria for substance abuse or dependence (alcohol, drugs) * With insufficient command of the French language * People with a deceased child * People who do not meet the diagnostic criteria for depressive disorder with peripartum onset (APA, 2013) * People who do not agree to take part in the study
Conditions Breast Cancer
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Observational, prospective, multicenter study. Collection of data relating to the effectiveness of sacituzumab govitecan SG, in a real-world context and planned research of predictive biomarkers of efficacy/tolerability carried out on multiple platforms at the center coordinator.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: data collection — Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability

Primary Outcomes

  • Biomolecular investigations conducted on multiple platforms (30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-17
Completion: 2027-06-17
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Regina Elena Cancer Institute
Collaborators: Ospedale Sandro Pertini, Roma, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Campus Bio-Medico University, Azienda Policlinico Umberto I, San Giovanni Addolorata Hospital, Ospedale "SS Annunziata", Chieti, Ospedale "Gaetano Bernabeo" , Ortona, Hospital San Pietro Fatebenefratelli, presidio Ospedaliero santo spirito in Sassia, Roma, Ospedale di Belcolle - Viterbo
Principal Investigators:
  • Patrizia Vici, Doctor (PRINCIPAL_INVESTIGATOR) - IRCCS "Regina Elena" National Cancer Institute
Contact Information
Study Contact:
Patrizia Vici, Doctor
06-5266.5584
patrizia.vici@ifo.it
Eriseld Krasniqi, Doctor
eriseld.krasniqi@ifo.it
Patrizia Vici, Doctor
06-5266.5584
patrizia.vici@ifo.it
"Regina Elena" National Cancer Institute
Interventions
  • Other: data collection — Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability
Study Locations (1 sites)
"Regina Elena" National Cancer Institute, Rome, Rome 00144 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * Histological diagnosis of TNBC; * Locally advanced unresectable or metastatic disease; * Indication for treatment with SG in monotherapy according to clinical practice (patients pre-treated with at least two lines of systemic therapy, of which at least one in an advanced stage); * Availability of at least one tumor tissue sample (from primary tumor or metastasis) to be sent to the coordinating center (IRE); * Written informed consent; * Availability to comply with the procedures established by the protocol, according to the methods and times described. Exclusion Criteria: * Patients with a history of other malignancies; * Contraindications to the use of sacituzumab govitecan SG; * Untreated and/or clinically unstable (symptomatic) brain metastases.
Conditions Breast Cancer, Breast Neoplasms
Phase NA
Enrollment 11
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to investigate the feasibility of a multimodal prehabilitation programme consisting of MIET during neoadjuvant intravenous chemotherapy infusion, HITT and strength training during the last six weeks prior to surgery, and optimising nutritional intake throughout the total preoperative period in patients with breast cancer with respect to recruitment, adherence, dropout, safety and acceptance. The secondary objective is to provide a preliminary evaluation of participant responses to a preoperative multimodal lifestyle intervention, on cardiorespiratory fitness, muscle strength, nutritional status, and fatigue in patients with breast cancer receiving neoadjuvant chemotherapy.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: A multimodal prehabilitation programme — 1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x): * 5 min. warm-up * 35 min. cycling at 40-60% of (HR reserve + resting HR) * 5-10 min. cool-down 2. \+ strength training During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x): HITT: * 3 min warm-up (20W) * 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down Muscle strength: 4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM. 3\) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week.

Primary Outcomes

  • Recruitment rate (%) (Week 0)
  • Characteristics of included participants (Week 0)
  • Attendance rate for MIET sessions (%) (Week 10-20)
  • Adherence rate, exercise relative dose intensity (ExRDI) MIET (%) (Week 10-20)
  • Reasons for not having executed a training session as intended (Week 10-20)
  • Attendance rate HIIT + strength sessions (%) (Week 17-22)
  • Adherence rate, ExRDI HIIT training (%) (Week 17-22)
  • Adherence rate, ErXDI strength training (%) (Week 17-22)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-27
Completion: 2025-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 11 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maastricht University Medical Center
Collaborators: Nationaal Fonds tegen Kanker
Principal Investigators:
  • Hanneke Dijk - Huisman, PhD (PRINCIPAL_INVESTIGATOR) - Maastricht University Medical Center
Contact Information
Study Contact:
Hanneke van Dijk - Huisman, PhD
+31 43 3877146
hanneke.huisman@mumc.nl
Anouk Weemaes, MSc
+31 43 3877146
anouk.weemaes@mumc.nl
Hanneke C. van Dijk - Huisman, Dr.
(+31)433877146
hanneke.huisman@mumc.nl
Maastricht University Medical Center
Interventions
  • Behavioral: A multimodal prehabilitation programme — 1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x): * 5 min. warm-up * 35 min. cycling at 40-60% of (HR reserve + resting HR) * 5-10 min. cool-down 2. \+ strength training During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x): HITT: * 3 min warm-up (20W) * 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down Muscle strength: 4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM. 3\) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week.
Study Locations (1 sites)
Maastricht University Medical Center, Maastricht, Limburg 6229HX Netherlands
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with stage I-III breast cancer eligible for neoadjuvant intravenous chemotherapy at the MUMC+ * Aged ≥18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status Scale grade 0-1 (Table 1) * Enough understanding of the Dutch language Exclusion Criteria: * Human Epidermal growth factor Receptor 2 (HER2) - positive tumour * Scalp cooling * Conditions that seriously hamper physical exercise * Incapacitated subjects as reported by the attending medical specialist in the medical record. When any doubt arises, the patient will not be considered eligible.